Financhill
Buy
80

TMDX Quote, Financials, Valuation and Earnings

Last price:
$124.22
Seasonality move :
18.31%
Day range:
$121.92 - $124.60
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
91.36x
P/S ratio:
9.30x
P/B ratio:
15.79x
Volume:
445.1K
Avg. volume:
1.2M
1-year change:
-9.66%
Market cap:
$4.2B
Revenue:
$441.5M
EPS (TTM):
$1.36

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TMDX
TransMedics Group
$123.4M $0.24 28.29% 22.47% $126.71
AXGN
Axogen
$48.3M $0.02 10.96% -76% $24.43
ELMD
Electromed
$15.8M -- 12.26% -- $37.00
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$9.2M -$0.08 21.89% -258.33% $9.05
STXS
Stereotaxis
$6.9M -$0.07 72.15% -3.57% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TMDX
TransMedics Group
$124.25 $126.71 $4.2B 91.36x $0.00 0% 9.30x
AXGN
Axogen
$11.07 $24.43 $504.2M -- $0.00 0% 2.55x
ELMD
Electromed
$19.65 $37.00 $164.8M 24.87x $0.00 0% 2.87x
IRIX
IRIDEX
$0.98 -- $16.5M -- $0.00 0% 0.33x
MYO
Myomo
$3.11 $9.05 $111.9M -- $0.00 0% 3.13x
STXS
Stereotaxis
$2.07 $4.50 $178M -- $0.00 0% 6.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TMDX
TransMedics Group
65.7% 3.653 22.41% 8.13x
AXGN
Axogen
31.17% 1.036 5.67% 2.22x
ELMD
Electromed
-- 2.545 -- 4.79x
IRIX
IRIDEX
81.05% 1.797 21.92% 1.11x
MYO
Myomo
-- 2.360 -- 2.24x
STXS
Stereotaxis
-- 1.450 -- 0.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TMDX
TransMedics Group
$88.2M $27.4M 6.8% 23.22% 21% -$29.9M
AXGN
Axogen
$34.9M -$1.7M -4.88% -7.2% -3.26% -$13.8M
ELMD
Electromed
$12.2M $2.1M 16.57% 16.57% 13.65% $2.2M
IRIX
IRIDEX
$5.1M -$205K -140.14% -218.69% -1.72% -$1.2M
MYO
Myomo
$6.6M -$3.5M -38.11% -38.11% -35.81% -$3.3M
STXS
Stereotaxis
$4.1M -$5.9M -174.6% -174.6% -79.35% -$1.8M

TransMedics Group vs. Competitors

  • Which has Higher Returns TMDX or AXGN?

    Axogen has a net margin of 17.89% compared to TransMedics Group's net margin of -7.9%. TransMedics Group's return on equity of 23.22% beat Axogen's return on equity of -7.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMDX
    TransMedics Group
    61.47% $0.70 $776.4M
    AXGN
    Axogen
    71.94% -$0.08 $153.1M
  • What do Analysts Say About TMDX or AXGN?

    TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 1.98%. On the other hand Axogen has an analysts' consensus of $24.43 which suggests that it could grow by 120.67%. Given that Axogen has higher upside potential than TransMedics Group, analysts believe Axogen is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMDX
    TransMedics Group
    5 3 0
    AXGN
    Axogen
    5 0 0
  • Is TMDX or AXGN More Risky?

    TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Axogen has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.457%.

  • Which is a Better Dividend Stock TMDX or AXGN?

    TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TMDX or AXGN?

    TransMedics Group quarterly revenues are $143.5M, which are larger than Axogen quarterly revenues of $48.6M. TransMedics Group's net income of $25.7M is higher than Axogen's net income of -$3.8M. Notably, TransMedics Group's price-to-earnings ratio is 91.36x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.30x versus 2.55x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMDX
    TransMedics Group
    9.30x 91.36x $143.5M $25.7M
    AXGN
    Axogen
    2.55x -- $48.6M -$3.8M
  • Which has Higher Returns TMDX or ELMD?

    Electromed has a net margin of 17.89% compared to TransMedics Group's net margin of 12.06%. TransMedics Group's return on equity of 23.22% beat Electromed's return on equity of 16.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMDX
    TransMedics Group
    61.47% $0.70 $776.4M
    ELMD
    Electromed
    77.97% $0.21 $43.9M
  • What do Analysts Say About TMDX or ELMD?

    TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 1.98%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 88.3%. Given that Electromed has higher upside potential than TransMedics Group, analysts believe Electromed is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMDX
    TransMedics Group
    5 3 0
    ELMD
    Electromed
    2 0 0
  • Is TMDX or ELMD More Risky?

    TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

  • Which is a Better Dividend Stock TMDX or ELMD?

    TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TMDX or ELMD?

    TransMedics Group quarterly revenues are $143.5M, which are larger than Electromed quarterly revenues of $15.7M. TransMedics Group's net income of $25.7M is higher than Electromed's net income of $1.9M. Notably, TransMedics Group's price-to-earnings ratio is 91.36x while Electromed's PE ratio is 24.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.30x versus 2.87x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMDX
    TransMedics Group
    9.30x 91.36x $143.5M $25.7M
    ELMD
    Electromed
    2.87x 24.87x $15.7M $1.9M
  • Which has Higher Returns TMDX or IRIX?

    IRIDEX has a net margin of 17.89% compared to TransMedics Group's net margin of -14.17%. TransMedics Group's return on equity of 23.22% beat IRIDEX's return on equity of -218.69%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMDX
    TransMedics Group
    61.47% $0.70 $776.4M
    IRIX
    IRIDEX
    42.49% -$0.10 $4.5M
  • What do Analysts Say About TMDX or IRIX?

    TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 1.98%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 104.08%. Given that IRIDEX has higher upside potential than TransMedics Group, analysts believe IRIDEX is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMDX
    TransMedics Group
    5 3 0
    IRIX
    IRIDEX
    0 0 0
  • Is TMDX or IRIX More Risky?

    TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

  • Which is a Better Dividend Stock TMDX or IRIX?

    TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TMDX or IRIX?

    TransMedics Group quarterly revenues are $143.5M, which are larger than IRIDEX quarterly revenues of $11.9M. TransMedics Group's net income of $25.7M is higher than IRIDEX's net income of -$1.7M. Notably, TransMedics Group's price-to-earnings ratio is 91.36x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.30x versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMDX
    TransMedics Group
    9.30x 91.36x $143.5M $25.7M
    IRIX
    IRIDEX
    0.33x -- $11.9M -$1.7M
  • Which has Higher Returns TMDX or MYO?

    Myomo has a net margin of 17.89% compared to TransMedics Group's net margin of -35.24%. TransMedics Group's return on equity of 23.22% beat Myomo's return on equity of -38.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMDX
    TransMedics Group
    61.47% $0.70 $776.4M
    MYO
    Myomo
    67.23% -$0.08 $21.7M
  • What do Analysts Say About TMDX or MYO?

    TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 1.98%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 191%. Given that Myomo has higher upside potential than TransMedics Group, analysts believe Myomo is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMDX
    TransMedics Group
    5 3 0
    MYO
    Myomo
    3 0 0
  • Is TMDX or MYO More Risky?

    TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

  • Which is a Better Dividend Stock TMDX or MYO?

    TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TMDX or MYO?

    TransMedics Group quarterly revenues are $143.5M, which are larger than Myomo quarterly revenues of $9.8M. TransMedics Group's net income of $25.7M is higher than Myomo's net income of -$3.5M. Notably, TransMedics Group's price-to-earnings ratio is 91.36x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.30x versus 3.13x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMDX
    TransMedics Group
    9.30x 91.36x $143.5M $25.7M
    MYO
    Myomo
    3.13x -- $9.8M -$3.5M
  • Which has Higher Returns TMDX or STXS?

    Stereotaxis has a net margin of 17.89% compared to TransMedics Group's net margin of -77.93%. TransMedics Group's return on equity of 23.22% beat Stereotaxis's return on equity of -174.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    TMDX
    TransMedics Group
    61.47% $0.70 $776.4M
    STXS
    Stereotaxis
    54.39% -$0.07 $8.2M
  • What do Analysts Say About TMDX or STXS?

    TransMedics Group has a consensus price target of $126.71, signalling upside risk potential of 1.98%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 117.39%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

    Company Buy Ratings Hold Ratings Sell Ratings
    TMDX
    TransMedics Group
    5 3 0
    STXS
    Stereotaxis
    2 0 0
  • Is TMDX or STXS More Risky?

    TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

  • Which is a Better Dividend Stock TMDX or STXS?

    TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TMDX or STXS?

    TransMedics Group quarterly revenues are $143.5M, which are larger than Stereotaxis quarterly revenues of $7.5M. TransMedics Group's net income of $25.7M is higher than Stereotaxis's net income of -$5.8M. Notably, TransMedics Group's price-to-earnings ratio is 91.36x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 9.30x versus 6.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TMDX
    TransMedics Group
    9.30x 91.36x $143.5M $25.7M
    STXS
    Stereotaxis
    6.49x -- $7.5M -$5.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock